Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04216303

Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Methodist Health System · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Major cardiovascular events are greatest in liver transplant recipients with sustained post-transplantation diabetes1. However, the optimal A1c target after transplantation has not been studied. The objective is to understand the optimal A1c target post liver and combined liver and kidney transplant. Strict A1c control will improve mortality and cardiovascular risk post liver and combined liver and kidney transplant and improve complications post liver and combined liver and kidney transplant.

Detailed description

Major cardiovascular events are greatest in liver transplant recipients with sustained post-transplantation diabetes. However, the optimal A1c target after transplantation has not been studied. The objective is to understand the optimal A1c target post liver and combined liver and kidney transplant. Strict A1c control will improve mortality and cardiovascular risk post liver and combined liver and kidney transplant and improve complications post liver and combined liver and kidney transplant. Strict blood sugar control in non-transplant patients with diabetes mellitus has shown unfavorable results in previous studies. However, no optimal A1c level has been studied in liver and combined liver and kidney transplant patients. Furthermore, guidelines for A1c target post-transplant are of expert opinion. The primary objective is to assess the impact of hemoglobin A1c on all-cause mortality among patients with diabetes mellitus undergoing liver or combined liver and kidney transplantation between 2008 to 2018. The second objective is to assess the impact of hemoglobin A1c on complications post liver or combined liver and kidney transplantation.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESThemoglobin A1cThe hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.

Timeline

Start date
2019-09-12
Primary completion
2021-08-19
Completion
2021-08-19
First posted
2020-01-02
Last updated
2021-09-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04216303. Inclusion in this directory is not an endorsement.